Cargando…

Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database

BACKGROUND: Evidence on neonatal withdrawal syndrome following antidepressant intrauterine exposure is limited, particularly for antidepressants other than selective serotonin reuptake inhibitor (SSRIs). METHODS: In our case/non-case pharmacovigilance study, based on VigiBase(®), the WHO database of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastaldon, C., Arzenton, E., Raschi, E., Spigset, O., Papola, D., Ostuzzi, G., Moretti, U., Trifirò, G., Barbui, C., Schoretsanitis, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482711/
https://www.ncbi.nlm.nih.gov/pubmed/36128628
http://dx.doi.org/10.1017/S0033291722002859
_version_ 1785102232281153536
author Gastaldon, C.
Arzenton, E.
Raschi, E.
Spigset, O.
Papola, D.
Ostuzzi, G.
Moretti, U.
Trifirò, G.
Barbui, C.
Schoretsanitis, G.
author_facet Gastaldon, C.
Arzenton, E.
Raschi, E.
Spigset, O.
Papola, D.
Ostuzzi, G.
Moretti, U.
Trifirò, G.
Barbui, C.
Schoretsanitis, G.
author_sort Gastaldon, C.
collection PubMed
description BACKGROUND: Evidence on neonatal withdrawal syndrome following antidepressant intrauterine exposure is limited, particularly for antidepressants other than selective serotonin reuptake inhibitor (SSRIs). METHODS: In our case/non-case pharmacovigilance study, based on VigiBase(®), the WHO database of suspected adverse drug reactions, we estimated reporting odds ratio (ROR) and the Bayesian information component (IC) with 95% confidence/credibility intervals (CI) as measures of disproportionate reporting of antidepressant-related neonatal withdrawal syndrome. Antidepressants were first compared to all other medications, then to methadone, and finally within each class of antidepressants: SSRIs, tricyclics (TCA) and other antidepressants. Antidepressants were ranked in terms of clinical priority, based on semiquantitative score ratings. Serious v. non-serious reports were compared. RESULTS: A total of 406 reports of neonatal withdrawal syndrome in 379 neonates related to 15 antidepressants were included. Disproportionate reporting was detected for antidepressants as a group as compared to all other drugs (ROR: 6.18, 95% CI 5.45–7.01, IC: 2.07, 95% CI 1.92–2.21). Signals were found for TCAs (10.55, 95% CI 8.02–13.88), followed by other antidepressants (ROR: 5.90, 95% CI 4.74–7.36) and SSRIs (ROR: 4.68, 95% CI 4.04–5.42). Significant disproportionality emerged for all individual antidepressants except for bupropion, whereas no disproportionality for any antidepressant was detected v. methadone. Eleven antidepressants had a moderate clinical priority score and four had a weak one. Most frequent symptoms included respiratory symptoms (n = 106), irritability/agitation (n = 75), tremor (n = 52) and feeding problems (n = 40). CONCLUSIONS: Most antidepressants are associated with moderate signals of disproportionate reporting for neonatal withdrawal syndrome, which should be considered when prescribing an antidepressant during pregnancy, irrespective of class.
format Online
Article
Text
id pubmed-10482711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-104827112023-09-08 Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database Gastaldon, C. Arzenton, E. Raschi, E. Spigset, O. Papola, D. Ostuzzi, G. Moretti, U. Trifirò, G. Barbui, C. Schoretsanitis, G. Psychol Med Original Article BACKGROUND: Evidence on neonatal withdrawal syndrome following antidepressant intrauterine exposure is limited, particularly for antidepressants other than selective serotonin reuptake inhibitor (SSRIs). METHODS: In our case/non-case pharmacovigilance study, based on VigiBase(®), the WHO database of suspected adverse drug reactions, we estimated reporting odds ratio (ROR) and the Bayesian information component (IC) with 95% confidence/credibility intervals (CI) as measures of disproportionate reporting of antidepressant-related neonatal withdrawal syndrome. Antidepressants were first compared to all other medications, then to methadone, and finally within each class of antidepressants: SSRIs, tricyclics (TCA) and other antidepressants. Antidepressants were ranked in terms of clinical priority, based on semiquantitative score ratings. Serious v. non-serious reports were compared. RESULTS: A total of 406 reports of neonatal withdrawal syndrome in 379 neonates related to 15 antidepressants were included. Disproportionate reporting was detected for antidepressants as a group as compared to all other drugs (ROR: 6.18, 95% CI 5.45–7.01, IC: 2.07, 95% CI 1.92–2.21). Signals were found for TCAs (10.55, 95% CI 8.02–13.88), followed by other antidepressants (ROR: 5.90, 95% CI 4.74–7.36) and SSRIs (ROR: 4.68, 95% CI 4.04–5.42). Significant disproportionality emerged for all individual antidepressants except for bupropion, whereas no disproportionality for any antidepressant was detected v. methadone. Eleven antidepressants had a moderate clinical priority score and four had a weak one. Most frequent symptoms included respiratory symptoms (n = 106), irritability/agitation (n = 75), tremor (n = 52) and feeding problems (n = 40). CONCLUSIONS: Most antidepressants are associated with moderate signals of disproportionate reporting for neonatal withdrawal syndrome, which should be considered when prescribing an antidepressant during pregnancy, irrespective of class. Cambridge University Press 2023-09 2022-09-21 /pmc/articles/PMC10482711/ /pubmed/36128628 http://dx.doi.org/10.1017/S0033291722002859 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Original Article
Gastaldon, C.
Arzenton, E.
Raschi, E.
Spigset, O.
Papola, D.
Ostuzzi, G.
Moretti, U.
Trifirò, G.
Barbui, C.
Schoretsanitis, G.
Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
title Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
title_full Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
title_fullStr Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
title_full_unstemmed Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
title_short Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
title_sort neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of vigibase, the who spontaneous reporting database
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482711/
https://www.ncbi.nlm.nih.gov/pubmed/36128628
http://dx.doi.org/10.1017/S0033291722002859
work_keys_str_mv AT gastaldonc neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT arzentone neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT raschie neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT spigseto neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT papolad neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT ostuzzig neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT morettiu neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT trifirog neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT barbuic neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase
AT schoretsanitisg neonatalwithdrawalsyndromefollowinginuteroexposuretoantidepressantsadisproportionalityanalysisofvigibasethewhospontaneousreportingdatabase